Cancer immunotherapy that is given to attention long time has recently made tremendous progress. Novartis’s Kymriah and Gilead’s Yescarta, two star CAR-T products, were approved by the European Union (EU) and becameRead More…
A recently published report summarizes the biomarker targets in both hematological and solid malignancies for CAR T cell therapy and discusses potential new biomarker target. A biomarker is an integral part ofRead More…
Recently, MaxCyte announced that the company’s chimeric antigen receptor (CAR) cell therapy for the treatment of solid tumors based on non-viral messenger RNA (mRNA) technology has been approved by the Food andRead More…
Chimeric antigen receptor T cell (CAR-T) therapy is a novel cellular immunotherapy method that introduces chimeric antigen receptors and costimulatory molecules targeting specific targets into T cells by gene editing technology. TumorRead More…
At the end of June this year, the CAR-NK cell, a new immune cell, was reported as the third CAR cell to fight against cancer after CAR-T cells and CAR-macrophage cells. TheRead More…
Cancers don’t come from anything but result from unexpected mutations in human cells with the uncontrolled proliferation of cells as the most important feature. The cells in the body undergo mutations atRead More…
On May 2, Johnson & Johnson, a pharmaceutical giant, announced that it has invested $1 billion in the acquisition of BeneVir Biopharm, a biotech-company dedicated to oncolytic virus immunotherapy research. This newsRead More…
A 72-year-old Connecticut citizen Bob Carlson was diagnosed with lung cancer four years ago. The doctor estimates that he will not live longer than two years. He tried a variety of programsRead More…
CAR-T cell immunotherapy, the chimeric antigen receptor T-cell immunotherapy, is a highly efficient and advanced cell immunotherapy. The principle is to genetically modify the immune cell T cells in patients to killRead More…
There is no doubt that the emergence of immunotherapy has redefined the field of cancer treatment as breakthrough progress. Most immunotherapies now focus on the adaptive immune response, that is, on TRead More…